Start500124 • BOM
Dr Reddy's Laboratories Ltd
1.179,85 ₹
28. jan., 16.01.35 GMT+5.30 · INR · BOM · Ansvarsfraskrivelse
AktieVærdipapir børsnoteret i INHovedkvarter i IN
Seneste lukkekurs
1.197,40 ₹
Dagsinterval
1.165,00 ₹ - 1.197,40 ₹
Årsinterval
1.120,01 ₹ - 1.420,20 ₹
Markedsværdi
983,16 mia. INR
Gns. volumen
95,72 t
P/E-værdi
18,32
Udbytteprocent
0,68 %
Primær børs
NSE
CDP Climate Change Score
A-
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(INR)dec. 2024År til år-ændring
Indtægt
83,59 mia.15,85 %
Driftsudgifter
30,34 mia.19,95 %
Nettoindtægt
14,13 mia.2,49 %
Overskudsgrad
16,91-11,51 %
Earnings per share
16,941,81 %
EBITDA
23,43 mia.13,31 %
Effektiv afgiftssats
25,10 %
Samlede aktiver
Samlede passiver
(INR)dec. 2024År til år-ændring
Kontanter og korttidsinvesteringer
59,92 mia.-17,41 %
Samlede aktiver
481,06 mia.29,02 %
Samlede passiver
159,49 mia.51,91 %
Samlet egenkapital
321,56 mia.
Shares outstanding
833,12 mio.
Kurs/indre værdi
3,14
Afkast af aktiver
9,88 %
Afkast af kapital
12,81 %
Nettoændring i likviditet
(INR)dec. 2024År til år-ændring
Nettoindtægt
14,13 mia.2,49 %
Pengestrøm fra drift
6,62 mia.39,75 %
Pengestrøm fra investering
-5,46 mia.66,27 %
Pengestrøm fra finansiering
590,00 mio.-88,83 %
Nettoændring i likviditet
1,75 mia.129,12 %
Fri pengestrøm
-382,75 mio.90,46 %
Om
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Administrerende direktør
Grundlagt
1984
Ansatte
27.048
Søgning
Ryd søgning
Luk søgning
Google-apps
Hovedmenu